Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBCAR269A +/- Nirogacestat in r/r MM
NCT04171843Phase 1Terminated
- Sponsor
- Precision BioSciences, Inc.
- Start
- Apr 2020
- Primary completion
- Oct 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PBCAR269A in multiple myeloma (MM) (6 cohorts), sponsored by Precision BioSciences, Inc. Primary endpoint: Maximum Tolerated Dose of PBCAR269A. Started Apr 2020; status: terminated.
02
Drugs
PBCAR269A
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04171843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171843.